Abstract:BACKGROUND The status of estrogen receptor-alpha (ER-alpha) expression is one of the most important diagnostic and prognostic factors of breast cancer. ER-alpha is a 66-kDa, ligand-induced transcription factor, characteristically detected in the cell nucleus by immunohistochemistry (IHC) in breast cancer specimens. Recently, we identified and cloned a 36-kDa novel variant of ER-alpha, ER-alpha36, which lacks both transactivation domains and functions as a dominant-negative effector of transactivation activities of the full-length ER-alpha (ER-alpha66) and ER-beta. ER-alpha36 primarily localizes to the cytoplasm and plasma membrane, and responds to both estrogens and antiestrogens by transducing membrane-initiated signaling cascades, stimulating proliferation and possibly contributing to a more aggressive phenotype in breast carcinomas. ER-alpha36 is expressed in established ER-positive and -negative breast cancer cell lines. However, its expression and localization in breast cancer specimens have not been evaluated. As ER-alpha36 may play important roles in breast cancer tumorigenesis, it is of clinical importance to examine the expression pattern of ER-alpha36, in addition to that of ER-alpha66, for more comprehensive molecular profiling of breast carcinomas. PATIENTS AND METHODS Thirty-one breast cancer patient tissues were evaluated for ER-alpha36 and ER-alpha66 protein expression status by IHC and six additional patient tissue samples were analyzed by Western blot analysis using antibodies specific to ER-alpha66 or ER-alpha36. RESULTS Our experiments reveal a cytoplasmic and plasma-membrane-associated expression pattern of ER-alpha36 in both ER-alpha66-positive and -negative breast cancer samples. Furthermore, ER-alpha36 expression appears to be associated with decreasing nuclear and/or cytoplasmic ER-alpha66 expression, suggesting its potential use as a diagnostic and prognostic marker. CONCLUSION ER-alpha36 is a novel isoform of ER-alpha, frequently expressed in ER-alpha66-negative cancers, whose detection may provide additional information for better diagnosis and prognosis.

Expression of ERα36 in gastric cancer samples and their matched normal tissues.

Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer.

Estrogen Receptor Beta Variants Mrna Expressions in Gastric Cancer Tissues and Association with Clinicopathologic Parameters

Prognostic Role of Estrogen Receptor Α and Estrogen Receptor Β in Gastric Cancer

ER-alpha36, a Novel Variant of ER-alpha, is Expressed in ER-positive and -Negative Human Breast Carcinomas.

Overexpression of ERα Inhibits Proliferation and Invasion of MKN28 Gastric Cancer Cells by Suppressing Β-Catenin

Transcriptional analysis of estrogen receptor alpha variant mRNAs in colorectal cancers and their matched normal colorectal tissues.

Expression of ER-α36, a novel variant of estrogen receptor in endometrial carcinoma and its clinical significance.

Estrogen-independent Effects of ER-α36 in ER-negative Breast Cancer

RETRACTED: Predictive and Prognostic Value of ER-α36 Expression in Breast Cancer Patients Treated with Chemotherapy

Quantitative Profiles of the Mrnas of ER-α and Its Novel Variant ER-α36 in Breast Cancers and Matched Normal Tissues

ER-α36 Promotes the Malignant Progression of Cervical Cancer Mediated by Estrogen via HMGA2

Expression of ER-{alpha}36, a Novel Variant of Estrogen Receptor {alpha}, and Resistance to Tamoxifen Treatment in Breast Cancer.

ER-α36: a Novel Biomarker and Potential Therapeutic Target in Breast Cancer.

Dystroglycan is Associated with Tumor Progression and Patient Survival in Gastric Cancer

Expression of Ngf Family and Their Receptors in Gastric Carcinoma: A Cdna Microarray Study

Prognostic Value of Amphiregulin and Epiregulin Mrna Expression in Metastatic Colorectal Cancer Patients

A primary study on the expression of estrogen receptor α36 in endometrial carcinoma tissues

ERα36 is an Effective Target of Epigallocatechin-3-gallate in Hepatocellular Carcinoma.

ROR alpha and REV-ERB alpha are Associated With Clinicopathological Parameters and are Independent Biomarkers of Prognosis in Gastric Cancer

Estrogen Receptor Alpha Variant Er Alpha 46 Mediates Growth Inhibition and Apoptosis of Human Ht-29 Colon Adenocarcinoma Cells in the Presence of 17 Beta-Oestradiol